A5101738543- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Computational Drug Discovery Methods
- Advanced Biosensing Techniques and Applications
- RNA modifications and cancer
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Molecular Biology Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Ocular Infections and Treatments
- Ferroptosis and cancer prognosis
- Cancer Cells and Metastasis
- Caveolin-1 and cellular processes
- Lung Cancer Treatments and Mutations
- Extracellular vesicles in disease
- Genetic factors in colorectal cancer
- Nanoplatforms for cancer theranostics
- Virus-based gene therapy research
- Traditional Chinese Medicine Studies
- Breast Cancer Treatment Studies
- Nanoparticle-Based Drug Delivery
- Immunotherapy and Immune Responses
- Inflammasome and immune disorders
- Ocular Surface and Contact Lens
Shanghai Cancer Institute
2024
Fudan University Shanghai Cancer Center
2021-2024
Shanghai Medical College of Fudan University
2021-2024
National Heart Lung and Blood Institute
2023-2024
National Institutes of Health
2023-2024
Wellcome/MRC Cambridge Stem Cell Institute
2023-2024
University of Cambridge
2023-2024
Wellcome Sanger Institute
2023-2024
Peking University
2024
Xiangya Hospital Central South University
2024
HER2-positive breast cancer is an aggressive subtype that accounts for 15% to 20% of all cancers. Recent studies have suggested a group heterogeneous diseases with different sensitivities standard treatment regimens. Revealing the molecular heterogeneity could potentially enable more precise strategies. In this study, we performed multiomics profiling on cohort and identified four transcriptome-based subtypes. The classical HER2 (HER2-CLA) comprised 28.3% samples displayed high ERBB2...
Triple-negative breast cancers (TNBCs), especially those non-immune-inflamed tumors, have a poor prognosis and limited therapies. Human leukocyte antigen (HLA)-I not only contributes to antitumor immune response the phenotype of tumor microenvironment, but also is negative predictor outcomes after immunotherapy. However, importance HLA functional status in TNBCs remains poorly understood. Using largest original multiomics datasets on TNBCs, we systematically characterized HLA-Ⅰ from...
<div>Abstract<p>HER2-positive breast cancer is an aggressive subtype that accounts for 15% to 20% of all cancers. Recent studies have suggested HER2-positive a group heterogeneous diseases with different sensitivities standard treatment regimens. Revealing the molecular heterogeneity could potentially enable more precise strategies. In this study, we performed multiomics profiling on cohort and identified four transcriptome-based subtypes. The classical HER2 (HER2-CLA) comprised...
Abstract The associated article reports multiomic analysis of breast cancers, where we provided a unique public resource that contributes novel insights into the cancer, holding promise for further precision treatment approaches. This protocol not only delineates detailed experimental procedures sample preparation and data generation but also comprehensive methods genomics, transcriptomics, proteomics, metabolomics from cancer samples. Furthermore, regarding radiomics pathomics, describes...
To characterize changes in the cornea nerve and pain responses fungal keratitis (FK).A retrospective analysis of vivo confocal microscopy images 11 FK corneas was performed, results were compared with those for normal corneas. Subbasal corneal nerves analyzed total number, main trunk branching patterns tortuosity. C57BL/6 mice infected Aspergillus fumigatus. Disease severity determined through clinical scoring slit lamp photography. Corneas harvested at 1, 3, 5, 7d post infection (p.i.)...
An efficient way to synthesize series of new urea- and thiocarbamate-tethered glycosyl β-amino acids under mild conditions was described.
Abstract Background: The standard approach of using one-size-fits-all endocrine therapy for hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancers has faced significant challenges due to variations in treatment response among individuals. Consequently, there is still an urgent need understand the molecular biology HR+/HER2- cancer explore precision strategy. Methods: We established a multiomics cohort (n = 351), multicenter real-world clinical cohorts 643), prospective (MULAN...
Abstract Background: While primary triple-negative breast cancer (TNBC) garners significant research attention, the genomic alterations that occur in metastasis remain insufficiently understood, especially within Asian populations. Furthermore, information obtained from tumor inadequately guides metastatic treatment, highlighting critical need for in-depth investigations into TNBC. Methods: We constructed largest cohort of TNBC metastases (n = 296) among advanced patients treated at Fudan...
Abstract Background: Immune checkpoint blockade (ICB) has substantially improved patient overall and progression-free survival in triple-negative breast cancer (TNBC), but its efficacy remains to be elucidated the hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) cancer, which is characterized by generally impotent lymphocytic infiltration. In I-SPY2 trial (NCT01042379), pembrolizumab- or durvalumab-containing neoadjuvant therapy increased pathologic...
<p>Figure S4</p>
<p>Table S1</p>
<p>Table S5</p>
<p>Figure S7</p>
<p>Table S4</p>
<p>Table S3</p>
<p>Figure S3</p>
<p>Table S2</p>
<p>Figure S1</p>
<p>Figure S2</p>